Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    NCT00134550
Previous Study | Return to List | Next Study

Improving Diabetic Foot Ulcers With Atorvastatin

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT00134550
Recruitment Status : Completed
First Posted : August 25, 2005
Last Update Posted : September 23, 2009
Sponsor:
Collaborator:
Pfizer
Information provided by:
Asker & Baerum Hospital

Tracking Information
First Submitted Date  ICMJE August 23, 2005
First Posted Date  ICMJE August 25, 2005
Last Update Posted Date September 23, 2009
Study Start Date  ICMJE February 2005
Actual Primary Completion Date March 2007   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: November 19, 2008)
  • To assess the efficacy of atorvastatin in patients with foot ulcers and type 1 or type 2 diabetes mellitus receiving conventional foot ulcer treatment in improving foot ulcer treatment with regards to completely healed DFU, recurrence of DFU or novel DFU [ Time Frame: 26 weeks ]
  • Time to complete healing (during 26 weeks of study) [ Time Frame: 26 weeks ]
  • Recurrence rate of foot ulcers (during 26 weeks of study) [ Time Frame: 26 weeks ]
Original Primary Outcome Measures  ICMJE
 (submitted: August 23, 2005)
  • To assess the efficacy of atorvastatin in patients with foot ulcers and type 1 or type 2 diabetes mellitus receiving conventional foot ulcer treatment in improving foot ulcer treatment with regards to:
  • 1. Number of ulcers completely healed within 12 weeks
  • 2. Time to complete healing (during 26 weeks of study)
  • 3. Recurrence rates of foot ulcers (during 26 weeks of study)
  • 4. Rate of reduction in wound size assessed at week 12 and week 26
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: November 19, 2008)
  • To assess the efficacy of atorvastatin in patients with foot ulcers and type 1 or type 2 diabetes mellitus receiving conventional foot ulcer treatment in improving: lipid variables and micro-CRP [ Time Frame: 26 weeks ]
  • Cost of DFU treatment from debut to healing (IDUS substudy) [ Time Frame: 2008 ]
Original Secondary Outcome Measures  ICMJE
 (submitted: August 23, 2005)
  • To assess the efficacy of atorvastatin in patients with foot ulcers and type 1 or type 2 diabetes mellitus receiving conventional foot ulcer treatment in improving
  • 1. Lipid variables and micro-crp
  • 2. Tissue oxygenation assessed by measurements of transcutaneous oxygen tension proximally, perilesional and distally of the foot ulcer
  • 3. Systolic toe pressure
  • 4. Inflammatory markers (IL-6, TNF-alpha)
  • 5. Other markers (BNP and advanced glycosilation end products (AGE))
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Improving Diabetic Foot Ulcers With Atorvastatin
Official Title  ICMJE Improving Diabetic Foot Ulcers With Atorvastatin
Brief Summary Lower limb complications are a substantial matter in the diabetic population and studies show that the annual incidence of foot ulcers ranges from 1.0-4.1% while the cumulative lifetime incidence is approximately 15%. Foot ulcers may become complicated by infection or gangrene, and ultimately result in amputation. In addition, foot ulcers have a significant impact on quality of life (QoL). The treatment of diabetic foot ulcers has not made substantial progress in recent years with regards to improved healing although there have been several actions taken to update the process. The current practice consists of wound debridement, treatment of underlying infections and pressure relief. This trial investigates the adjunctive effects of high (80 mg) or low (10 mg) dose atorvastatin to conventional treatment on the healing of diabetic foot ulcers.
Detailed Description

The diabetic foot ulcer etiology is multiplex and the wound healing is often not very successful due to various reasons. The ulcer's etiology is associated with peripheral vascular disease, autonomic neuropathy and endothelial. There may also be present some metabolic conditions that are not optimal for wound-healing, delaying the process even more (hyperglycemia, hyperlipidemia, hyperinsulinemia, pro-coagulative state).

It has been shown that statins may improve these aspects making the use of this as adjuvant therapy in treating diabetic foot ulcers an interesting theory. There is so far not any direct evidence for this, although documentation exists for several other possible associated conditions.

This study aims to elucidate the pleiotropic effects of atorvastatin on the healing of diabetic foot ulcers.

Material and Methods:

This 26-week prospective randomised, open, study will be conducted as a pilot to assess the efficacy of atorvastatin in improving diabetic foot-ulcer healing. Atorvastatin will be given in two dosages (10 mg and 80 mg) and evaluations between these groups will be done with regards to improvement in foot ulcer healing, microcirculation and inflammatory markers.

We aim to include 24 patients with diabetes (both type 1 and 2), over the age of 30, of both genders who have a wound duration of less than 12 months. The patients will be recruited from the diabetic out-patient clinics in two centers (Sarpsborg Hospital and Asker and Baerum Hospital).

Study Plan:

We plan to begin the enrolment of eligible patients in autumn 2004. We plan for a 18 month inclusion period and hope to conclude this pilot study by autumn 2006. Results from the study will be presented in international papers or meetings concerning diabetes and complications.

Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 2
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE
  • Foot Ulcer
  • Diabetes
Intervention  ICMJE Drug: Atorvastatin (10 mg or 80 mg)
Study Arms  ICMJE Not Provided
Publications * Healing of diabetic foot ulcers may be modified by high dose atorvastatin - a 6 month randomised controlled pilot trial European Association for the Study of Diabetes 2008 Johansen OE, Birkeland KI, Jørgensen AP, Orvik E, Sørgård B, Torjussen BR, Ueland T, Aukrust P, Gullestad L Diabetologia 2008;51(S1):S515.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: November 19, 2008)
13
Original Enrollment  ICMJE
 (submitted: August 23, 2005)
20
Actual Study Completion Date  ICMJE March 2007
Actual Primary Completion Date March 2007   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Provision of a written informed consent at the enrolment visit
  • Men or women above 30 years of age
  • Fertile women need to take contraceptives or have to be sterilised
  • Diagnosed with any diabetes mellitus type 1 or type 2
  • Present foot ulcer with an ulcer duration <= 12 months

Exclusion Criteria:

  • Intolerance to statins at any time in the past.
  • Unwillingness to participate
  • A history of alcohol or drug abuse within the last 2 years
  • Foot ulcer with the etiology from vasculitis, pyoderma gangrenosum, angiodermatitis necroticans (hypertensive ulcer), necrobiosis lipoidica, hydrostatic pressure/venous insufficiency or any neoplasms (basalioma, kaposis sarcoma, squamous cell carcinoma etc).
  • History of drug-induced hepatitis or previous liver enzyme elevations (> 3 times the upper limit of normal) while taking statins.
  • History of drug-induced creatine phosphokinase (CPK) > 3 times the upper limit of normal.
  • Critical limb ischemia that requires re-vascularisation procedures within 2 months
  • Brachial-ankle index < 0.5
  • Other serious or unstable medical or psychological conditions that, in the opinion of the investigator, would compromise the patient's safety or successful participation in the trial.
  • Any clinically significant abnormality identified in the enrolment medical history, physical examination, laboratory test which, in the judgement of the investigator, would preclude safe completion of the study.
  • Active liver disease or hepatic dysfunction defined as ALAT or ASAT elevations > 2 times the upper limit of normal or total bilirubin > 1.5 times the upper limit of normal.
  • Pregnancy
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 30 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Norway
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT00134550
Other Study ID Numbers  ICMJE The IDUS trial
Has Data Monitoring Committee No
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Odd Erik Johansen
Study Sponsor  ICMJE Asker & Baerum Hospital
Collaborators  ICMJE Pfizer
Investigators  ICMJE
Study Chair: Odd E Johansen, MD Asker and Baerum Hospital
PRS Account Asker & Baerum Hospital
Verification Date September 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP